Portfolio company
Isis Pharmaceuticals
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biotechnology firm develops antisense medicines to treat patients with rare and cardiovascular diseases by targeting RNA-based genetic pathways.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Arthex
This biotechnology company develops antisense RNA medicines to treat patients with rare genetic neuromuscular disorders such as myotonic dystrophy type 1.
Alnylam Pharmaceuticals
This biopharmaceutical company develops and commercialises RNA interference therapeutics to treat patients with rare, genetic, cardio-metabolic, and infectious diseases.
AveXis
This biotechnology firm develops gene therapies for patients with rare and life-threatening neurological genetic diseases including spinal muscular atrophy.
Arrakis Therapeutics
This biopharmaceutical company develops oral, small-molecule medicines that target RNA to treat patients with cancer, cardiovascular conditions, neurodegeneration and rare genetic diseases.
Sisaf
This company develops RNA delivery technologies and nucleic acid medicines for pharmaceutical partners treating rare genetic diseases and cancers.
Dicerna
This biotechnology firm develops ribonucleic acid interference therapies for patients with rare genetic, cardiovascular and liver diseases through a proprietary gene-silencing technology platform.
Marina
This company develops nucleic acid therapeutics and delivery technologies for patients with rare diseases, arthritis, hypertension, and cancer.
Phlox Therapeutics
This company develops RNA-based gene therapies to treat patients with rare genetic heart diseases, including cardiomyopathies and laminopathies.